1768P Genome-wide association study to identify genetic markers predictive of early-onset capecitabine-induced toxicity

Abstract

5-FU and its oral pro-drug capecitabine are widely used chemotherapy but associated toxicities are common and potentially fatal. The current strategy of DPYD testing is limited by low sensitivity, possibly due to causal variants lying outside the fluoropyrimidine pathway. We performed a genome wide association study (GWAS) to identify novel genetic markers that can predict serious early capecitabine toxicity.